

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: MATICA ENTERPRISES INC. (the "Issuer").

Trading Symbol: MMJ

Number of Outstanding Listed Securities: 300,340,909

Date: November 2, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company is pleased that RoyalMax Biotechnologies ("RoyalMax") has been granted a license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") for the production facility in Dorval, Quebec. Matica has now earned a 70% position in RoyalMax. The Company continues to make progress on the

greenhouse project in Hemmingford Quebec. The Company plans to build 1,000,000 sq ft of greenhouses on the 181 acre farm in Hemmingford in 200,000 sq ft increments.

Matica received 525,000 common shares of Cultivator Catalyst Corp. ("CCC") as full settlement of the legal claims filed by Matica against THC Dispensaries Canada Inc. ("THCD") for the \$695,000 previously invested by Matica in THCD. Subsequent to September 30, 2018, the 525,000 common shares of CCC have been exchanged for 2,625,000 common shares of Biome Grow Inc. which has just begun trading under the symbol BIO on the CSE.

2. Provide a general overview and discussion of the activities of management.

Management has begun preparation to receive clones and begin growing cannabis at the newly licensed growing facility in Dorval.

Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Matica has earned a 70% in RoyalMax Biotechnology Canada Inc. as per the April 5, 2017 investment agreement.

7. Describe the acquisition of new customers or loss of customers.

None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
None.
9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
None.
10. Report on any labour disputes and resolutions of those disputes if applicable.
None.
11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
None.
12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
None.
13. Provide details of any securities issued and options or warrants granted.
Management has initiated its first tranche of \$500,000 from the draw-down equity facility of up to \$20,000,000, with Alumina Partners, LLC. 4,000,000 shares were issued at \$0.125 cents with an equal number of warrants with an exercise price of \$0.205. There were no fees or commissions paid in association with this financing.
990,000 shares were issues as a result of warrants exercised at \$0.10.
14. Provide details of any loans to or by Related Persons.
None
15. Provide details of any changes in directors, officers or committee members.
None
16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 2, 2018

Boris Ziger
Name of Director or Senior
Officer

Boris Ziger
Signature
Director
Official Capacity

Issuer Details Name of Issuer Matica Enterprises Inc.	For Month End September 2018	Date of Report YY/MM/DD 18/11/02
Issuer Address 44 Victoria Street Ste. 1102 Toronto, ON, M5C 1Y2		
City/Province/Postal Code Toronto	Issuer Fax No.	Issuer Telephone No. (416) 304-9935
Contact Name Boris Ziger	Contact Position CEO	Contact Telephone No. (416) 304-9935
Contact Email Address info@maticaenterprises.com	Web Site Address www.maticaenterprises.com	

